Interaction of the combined medication with the new low-molecular-weight heparinoid Lomoparan (Org 10172) and acenocoumarol.
A high intravenous dose of the low-molecular-weight heparinoid Lomoparan (Org 10172) was administered to 6 healthy males in a steady state of anticoagulation (Thrombotest) by acenocoumarol. Prothrombin time, activated partial thromboplastin time and Stypven time were prolonged to a degree which was greater than that expected on the base of the summation of the effects by each drug alone. This effect was observed for a period of up to 1 h. The Thrombotest was affected for up to 5 h after the intravenous administration of Org 10172, therefore it is deemed unsuitable for monitoring the combined effects of these two anticoagulants during this period. Acenocoumarol did not affect the pharmacokinetic parameters of Org 10172 with the exception of a slight reduction of the clearance of plasma anti-Xa activity.
Stiekema
J C
JC
Scientific Development Group, Organon International BV, Oss, The Netherlands.
de Boer
A
A
Danhof
M
M
Kroon
C
C
Broekmans
A W
AW
van Dinther
T G
TG
Voerman
J
J
Breimer
D D
DD
D000074:Acenocoumarol / Q000493:pharmacokinetics / Q000494:pharmacology*; D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000032:analysis; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004357:Drug Synergism; D006025:Glycosaminoglycans / Q000493:pharmacokinetics / Q000494:pharmacology*; D006496:Heparinoids / Q000493:pharmacokinetics / Q000494:pharmacology*; D006497:Heparan Sulfate; D006801:Humans; D008297:Male; D010314:Partial Thromboplastin Time; D011517:Prothrombin Time; D011897:Random Allocation
D000074:Acenocoumarol; D001779:Blood Coagulation Factors; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006025:Glycosaminoglycans; D006496:Heparinoids; D006497:Heparan Sulfate; C035838:danaparoid